Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Latest Semaglutide News and Research

Semaglutide shown to cut major adverse cardiovascular events in heart failure patients

Semaglutide shows promise in reducing cardiovascular risks in obese patients with heart failure, improving outcomes in a recent large-scale clinical trial.

27 Aug 2024

Study warns of high Medicare costs for semaglutide even with restrictive CVD definition

If Medicare Part D narrowly defines cardiovascular disease, the majority of patients would remain ineligible while new federal spending could still exceed $10 billion

27 Aug 2024

GLP-1 therapy boosts visceral fat metabolism, driving weight loss

Researchers discuss the role of enhanced visceral adipose tissue metabolism in mediating weight loss by glucagon-like peptide-1 drugs.

26 Aug 2024

Clarification urgently needed for detected signal of semaglutide-linked suicidal ideation

Researchers investigate the potential link between the obesity drugs semaglutide and liraglutide and suicidal or self-injurious adverse drug reactions.

26 Aug 2024

Understanding the health benefits of polyphenols through bitter taste receptors

Bioactive compounds like polyphenols and their health benefits have long captured public attention and interest.

23 Aug 2024

Anti-obesity medication may help to prevent heart attacks and other major cardiac events

The anti-obesity medication semaglutide may help to prevent heart attacks and other major adverse cardiac events among overweight people who have cardiovascular disease, whether or not they also have heart failure, according to a new study led by UCL's Professor John Deanfield.

22 Aug 2024

New research challenges belief that weight loss drugs only reduce appetite

A study carried out in St Vincent's University Hospital (SVUH) Dublin challenges the belief that weight loss medications such as Ozempic, Wegovy or Monjaro work just by promoting satiety and making you eat less.

22 Aug 2024

Gut molecule blocks fat burning during fasting in C. elegans

In a struggle that probably sounds familiar to dieters everywhere, the less a Caenorhabditis elegans (C. elegans) worm eats, the more slowly it loses fat.

21 Aug 2024

High-protein diets: How they affect weight, energy, and blood sugar levels

Researchers review the effects of dietary protein on energy intake, appetite, and postprandial glycemia.

21 Aug 2024

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

Whether antidiabetic medications could potentially be used as disease-modifying osteoarthritis drugs or DMOADs for the therapeutic management of osteoarthritis.

21 Aug 2024

How little Denmark got homegrown giant Novo Nordisk to lower ozempic prices

On May 13, Sen. Bernie Sanders (I-Vt.) published an open letter to Novo Nordisk on the front page of a leading Danish newspaper, urging the hometown company to live up to its altruistic standards by lowering U.S. prices for its blockbuster diabetes and weight loss drugs.

8 Aug 2024

Public insurance recipients less likely to receive diabetes and obesity drug, study reveals

A new USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with private insurance.

2 Aug 2024

$Study reveals obesity's impact on muscle structure in heart failure with preserved ejection fraction$

Study reveals obesity's impact on muscle structure in heart failure with preserved ejection fraction

A new small study led by Johns Hopkins Medicine researchers and published July 25th in the journal Nature Cardiovascular Research has revealed the impact of obesity on muscle structure in patients having a form of heart failure called heart failure with a preserved ejection fraction (HFpEF).

1 Aug 2024

Weight loss guaranteed! But what impact on your diet? A review of GLP-1 and GIP/GLP-1 interventions

Researchers reviewed studies on dietary impacts of GLP-1 and GIP/GLP-1 receptor agonists in obesity and T2D patients, finding significant caloric reduction but limited evaluation of dietary composition.

29 Jul 2024

New scoring system enhances identification of HFpEF patients

A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

29 Jul 2024

Semaglutide may reduce smoking risks for diabetes patients

Semaglutide shows promise in reducing tobacco use disorder-related health encounters in patients with type 2 diabetes, but further clinical trials are needed to confirm its efficacy.

29 Jul 2024

Pharmacist cautions against self-medicating with ozempic for dementia risk reduction

“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England.

29 Jul 2024

GLP-1-based polyagonists: A promising weight loss alternative to bariatric surgery

Researchers highlight the unprecedented success of GLP-1-based multi-receptor drugs in achieving substantial weight loss and improved health outcomes, potentially replacing bariatric surgery for obesity treatment.

28 Jul 2024

How diet affects metabolism and the gut microbiome

In a recent review, researchers explored advances in molecular nutrition, focusing on pharmaceutical and dietary interventions for energy balance and their interactions with the gut microbiome. They also discussed emerging dietary patterns and the implications of microbiome research on nutrition.

28 Jul 2024

Older adults show interest in deprescribing, study reveals

More than 82% of Americans age 50 to 80 take one or more kinds of prescription medication, and 80% of them say they'd be open to stopping one or more of those drugs if their health care provider gave the green light, a new University of Michigan study shows.

24 Jul 2024

Semaglutide

Latest Semaglutide News and Research

Semaglutide shown to cut major adverse cardiovascular events in heart failure patients

Study warns of high Medicare costs for semaglutide even with restrictive CVD definition

GLP-1 therapy boosts visceral fat metabolism, driving weight loss

Clarification urgently needed for detected signal of semaglutide-linked suicidal ideation

Understanding the health benefits of polyphenols through bitter taste receptors

Anti-obesity medication may help to prevent heart attacks and other major cardiac events

New research challenges belief that weight loss drugs only reduce appetite

Gut molecule blocks fat burning during fasting in C. elegans

High-protein diets: How they affect weight, energy, and blood sugar levels

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

How little Denmark got homegrown giant Novo Nordisk to lower ozempic prices

Public insurance recipients less likely to receive diabetes and obesity drug, study reveals

Study reveals obesity's impact on muscle structure in heart failure with preserved ejection fraction

Weight loss guaranteed! But what impact on your diet? A review of GLP-1 and GIP/GLP-1 interventions

New scoring system enhances identification of HFpEF patients

Semaglutide may reduce smoking risks for diabetes patients

Pharmacist cautions against self-medicating with ozempic for dementia risk reduction

GLP-1-based polyagonists: A promising weight loss alternative to bariatric surgery

How diet affects metabolism and the gut microbiome

Older adults show interest in deprescribing, study reveals

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

A Discussion with Hologic’s Tim Simpson on the Future of Cervical Cancer Screening

Semaglutide

Latest Semaglutide News and Research

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

A Discussion with Hologic’s Tim Simpson on the Future of Cervical Cancer Screening

Newsletters you may be interested in